Coronavirus Live Count Map India
remove_red_eye 1335 Views
COVID-19 Vaccine Updates
#Allergy and Immunology
Common cold with cough is one of the most common condition experienced in clinical practice. Dry cough is the result of irritation of the posterior pharyngeal wall caused due to the post nasal drip, a common manifestation of common cold. This condition is distressing and may affect quality of life of an individual infected with common cold. Evidence based observations suggest that a combination of Phenylephrine (a nasal decongestant), chlorpheniramine maleate (an antihistaminic) and Dextromethorphan (an antitussive) are widely used in the treatment of common cold with dry cough.
The current Phase IV study determined the effectiveness and safety of the combination of Phenylephrine, Chlorpheniramine maleate and Dextromethorphan in the treatment of common cold with dry cough. The study enrolled a total 201 patients, among which 160 patients completed the study whereas 41 patients were not available for follow up. Analysis of therapeutic potential of the combination was made by the reduction in total symptom score (TSS) and four point Likert-type scales. The tolerability profile was assessed by determining the incidence of adverse events during the trial.
The result divulged a reduction in TSS from 6.58 (baseline) to 4.27 (day 3) and 1.53 (day 5). A total of 49 episodes of adverse events with mild intensity were observed.
Therefore, a combination of Phenylephrine, Chlorpheniramine maleate and Dextromethorphan is a safe and efficacious therapy in the treatment of common cold with dry cough.
Source: Kiran M, Sharvari L, Pawaskar L. Efficacy and safety of a combination of phenylephrine, chlorpheniramine and dextromethorphan in cold and dry cough in children. 2017;10.